Since being founded in 1992, MorphoSys has been one of the most
closely followed German biotechnology companies, and from the beginning
it has been entrusted with great expectations. From its start as a core
team of young researchers, it has grown into a globally operating
organization with 340 employees. Within the small and exclusive group
of antibody experts worldwide, MorphoSys is viewed as a technology
leader and the partner of choice for antibody development.
A Constant in the German and International Capital Markets
In 1999, MorphoSys became the first German biopharmaceutical company
to trade its shares publicly. Today, MorphoSys is one of the top ten
biotechnology stocks in Europe. MorphoSys is listed within the Prime
Standard of the German Exchange in Frankfurt and the technology index
TecDAX. Based on its stable business model, which has delivered
uninterrupted growth over many years, its sustained profitability since
2004, and its balanced risk profile, MorphoSys is considered a
fundamental investment among European biotechnology stocks. Even in the
financial crisis year of 2008, the MorphoSys share closed the year at
the top of the TecDAX with an increase of 16% in value. This year, the
company celebrates its tenth anniversary as a public company, and looks
forward to an exciting future of continuing innovation and growth.
